SCHEMBL6222525

SCHEMBL6222525

CC(C)(C)OC(=O)N1CCCCC1CNC(=O)Nc1ccc(F)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
FPR3 P25089 1/20 0.53
FPR2 P25090 1/20 0.53
OPRD1 P41143 1/20 0.50
HCRTR1 O43613 3/20 0.48
HCRTR2 O43614 3/20 0.48
NPC1 O15118 1/20 0.47
KDM1A O60341 1/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
APP P05067 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA2A P08913 1/20 0.44
DRD2 P14416 1/20 0.44
ADRA2B P18089 1/20 0.44
ADRA2C P18825 1/20 0.44
SLC6A2 P23975 1/20 0.44
HRH2 P25021 1/20 0.44
HTR1D P28221 1/20 0.44
HTR1B P28222 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6223213 0.89 HCRTR1 (0.60) FPR3FPR2OPRD1HCRTR1HCRTR2
SCHEMBL6223216 0.89 HCRTR1 (0.60) FPR3FPR2OPRD1HCRTR1HCRTR2
SCHEMBL15891825 0.87 ALDH1A1 (0.52) ALDH1A1FPR3FPR2OPRD1HCRTR1
SCHEMBL4956334 0.86 OPRD1 (0.59) FPR3FPR2OPRD1HCRTR1HCRTR2
SCHEMBL6223994 0.85 HCRTR1 (0.57) ALDH1A1FPR3FPR2OPRD1HCRTR1
SCHEMBL6223990 0.85 HCRTR1 (0.57) ALDH1A1FPR3FPR2OPRD1HCRTR1
SCHEMBL13853714 0.80 OPRD1 (0.51) ALDH1A1FPR3FPR2OPRD1KDM1A
SCHEMBL20794631 0.78 APP (0.48) ALDH1A1FPR3FPR2OPRD1NPC1
SCHEMBL3693406 0.78 APP (0.48) ALDH1A1FPR3FPR2OPRD1NPC1
SCHEMBL3693402 0.78 APP (0.48) ALDH1A1FPR3FPR2OPRD1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1289955-B1 PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2005-04-13 EP disclosed
US-6677354-B2 TREATING SLEEP, BRAIN, SEXUAL, CARDIOVASCULAR, NERVOUS SYSTEM, PSYCHOLOGICAL, GLANDULAR, AND GASTROINTESTINAL DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2004-01-13 US disclosed
US-20030186964-A1 Piperdines for use as orexin receptor antagonists SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-02 US disclosed
EP-1289955-A1 PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2003-03-12 EP disclosed
WO-2001096302-A1 PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM P.L.C. (GB) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186964-A1 Piperdines for use as orexin receptor antagonists HCRTR2, HCRTR1, NPSR1 ALDH1A1 1133/4885FPR3 153/4885FPR2 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.